Figure 7. The selective p38 inhibitor SB203580 attenuates bortezomib- and GSK2830371/bortezomib-induced lethality.

Z-138, JVM-2, and MAVER-1 cells were exposed to GSK2830371 and bortezomib in the presence or absence of the selective p38 inhibitor SB203580; the annexin V-positive fractions were determined after 72 hours. SB203580 was added to the cells 30 minutes before the administration of GSK2830371 or bortezomib.